Plus Therapeutics, INC Form 4 insider transactions

A director at Plus Therapeutics, An van Es-Johansson, was granted 297,794 stock options with an exercise price of $0.5744, vesting over 12 months.

Director Richard J. Hawkins acquired stock options in Plus Therapeutics, Inc. on February 18, 2025.

Director Howard Clowes acquired stock options in Plus Therapeutics, Inc. on February 18, 2025.

Andrew Sims, CFO of Plus Therapeutics, was granted stock options to purchase 60,020 shares of common stock at an exercise price of $1.18, vesting monthly over four years.

Robert P. Lenk, a director of Plus Therapeutics, Inc., acquired stock options exercisable for 40,122 shares of common stock on February 18, 2025.

An van Es-Johansson, a director of Plus Therapeutics, Inc., acquired stock options on February 18, 2025.

CEO of Plus Therapeutics, Marc Hedrick, was granted stock options on February 18, 2025.

Director Greg Petersen of Plus Therapeutics acquired stock options on February 18, 2025, according to a Form 4 filing.

Director Richard J Hawkins purchased 4,000 shares of Plus Therapeutics at an average price of $1.499 on September 13, 2024.

Director Richard J. Hawkins of Plus Therapeutics reports the acquisition and disposal of common stock on September 12, 2024.

Director Greg Petersen increased his holdings in Plus Therapeutics by purchasing 12,500 shares of common stock at $1.35 per share on September 11, 2024.

Director Howard Clowes purchased 5,000 shares of Plus Therapeutics (PSTV) at $1.3362 per share on September 11, 2024.

Director Richard J. Hawkins acquired stock options in Plus Therapeutics, Inc. on September 11, 2024.

An van Es-Johansson, a director of Plus Therapeutics, Inc., acquired stock options exercisable for 3,650 shares of common stock on September 11, 2024.

Robert P. Lenk, a director of Plus Therapeutics, Inc., acquired stock options exercisable for 3,650 shares of common stock on September 11, 2024.

Director Greg Petersen acquired stock options in Plus Therapeutics, Inc. on September 11, 2024.

Howard Clowes, a director of Plus Therapeutics, acquired stock options exercisable for 3,650 shares of common stock on September 11, 2024.

Andrew John Hugh MacIntyre Sims, CFO of Plus Therapeutics, acquired stock options on September 11, 2024.

Plus Therapeutics CEO Marc Hedrick was granted stock options to purchase 197,595 shares of common stock.

Andrew Sims, CFO of Plus Therapeutics, reported the acquisition of 4,098 shares of common stock at $1.27 per share on September 10, 2024.

Plus Therapeutics CEO, Marc Hedrick, recently purchased 8,000 shares of the company's common stock at an average price of $1.2299 per share.

Andrew Sims, CFO of Plus Therapeutics, reports acquisition of common stock and warrants.

Plus Therapeutics CEO Marc Hedrick recently acquired shares and warrants of the company's common stock.

Director Greg Petersen of Plus Therapeutics reports the acquisition and disposal of common stock and warrants.

Director Howard Clowes reports acquisition of Plus Therapeutics common stock and warrants.

Director Richard J. Hawkins reports acquisition of Plus Therapeutics common stock and warrants.

Director Robert P. Lenk reports acquisition and disposal of Plus Therapeutics (PSTV) common stock and warrants on May 8, 2024.